Antidepressant Monotherapy vs Sequential Pharmacotherapy and Mindfulness-Based Cognitive Therapy, or Placebo, for Relapse Prophylaxis in Recurrent Depression | Depressive Disorders | JAMA Psychiatry | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.185.54. Please contact the publisher to request reinstatement.
1.
Judd  LLAkiskal  HSZeller  PJPaulus  MLeon  ACMaser  JDEndicott  JCoryell  WKunovac  JLMueller  TIRice  JPKeller  MB Psychosocial disability during the long-term course of unipolar major depressive disorder.  Arch Gen Psychiatry 2000;57 (4) 375- 380PubMedGoogle Scholar
2.
American Psychiatric Association, Practice guideline for the treatment of patients with major depressive disorder (revision).  Am J Psychiatry 2000;157 (4) ((suppl)) 1- 45PubMedGoogle Scholar
3.
Bockting  CLten Doesschate  MCSpijker  JSpinhoven  PKoeter  MWSchene  AHDELTA Study Group, Continuation and maintenance use of antidepressants in recurrent depression.  Psychother Psychosom 2008;77 (1) 17- 26PubMedGoogle Scholar
4.
Simon  GEVon Korff  MRutter  CMPeterson  DA Treatment process and outcomes for managed care patients receiving new antidepressant prescriptions from psychiatrists and primary care physicians.  Arch Gen Psychiatry 2001;58 (4) 395- 401PubMedGoogle Scholar
5.
Fava  GARuini  CRafanelli  C Sequential treatment of mood and anxiety disorders.  J Clin Psychiatry 2005;66 (11) 1392- 1400PubMedGoogle Scholar
6.
Post  RM Transduction of psychosocial stress into the neurobiology of recurrent affective disorder.  Am J Psychiatry 1992;149 (8) 999- 1010PubMedGoogle Scholar
7.
Fava  GARafanelli  CGrandi  SConti  SBelluardo  P Prevention of recurrent depression with cognitive behavioral therapy: preliminary findings.  Arch Gen Psychiatry 1998;55 (9) 816- 820PubMedGoogle Scholar
8.
Fava  GARuini  CRafanelli  CFinos  LConti  SGrandi  S Six-year outcome of cognitive behavior therapy for prevention of recurrent depression.  Am J Psychiatry 2004;161 (10) 1872- 1876PubMedGoogle Scholar
9.
Bockting  CLSpinhoven  PWouters  LFKoeter  MWSchene  AHDELTA Study Group, Long-term effects of preventive cognitive therapy in recurrent depression: a 5.5-year follow-up study.  J Clin Psychiatry 2009;70 (12) 1621- 1628PubMedGoogle Scholar
10.
Teasdale  JDSegal  ZVWilliams  JMRidgeway  VASoulsby  JMLau  MA Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy.  J Consult Clin Psychol 2000;68 (4) 615- 623PubMedGoogle Scholar
11.
Bondolfi  GJermann  Fder Linden  MVGex-Fabry  MBizzini  LRouget  BWMyers-Arrazola  LGonzalez  CSegal  ZAubry  JMBertschy  G Depression relapse prophylaxis with Mindfulness-Based Cognitive Therapy: replication and extension in the Swiss health care system.  J Affect Disord 2010;122 (3) 224- 231PubMedGoogle Scholar
12.
Kuyken  WByford  STaylor  RSWatkins  EHolden  EWhite  KBarrett  BByng  REvans  AMullan  ETeasdale  JD Mindfulness-based cognitive therapy to prevent relapse in recurrent depression.  J Consult Clin Psychol 2008;76 (6) 966- 978PubMedGoogle Scholar
13.
Raue  PJSchulberg  HCHeo  MKlimstra  SBruce  ML Patients' depression treatment preferences and initiation, adherence, and outcome: a randomized primary care study.  Psychiatr Serv 2009;60 (3) 337- 343PubMedGoogle Scholar
14.
Clayton  AKeller  A McGarvey  EL Burden of phase-specific sexual dysfunction with SSRIs.  J Affect Disord 2006;91 (1) 27- 32PubMedGoogle Scholar
15.
Pedersen  LHHenriksen  TBVestergaard  MOlsen  JBech  BH Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study.  BMJ 2009;339b3569PubMedGoogle Scholar
16.
Trivedi  MHRush  AJCrismon  MLKashner  TMToprac  MGCarmody  TJKey  TBiggs  MMShores-Wilson  KWitte  BSuppes  TMiller  ALAltshuler  KZShon  SP Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project.  Arch Gen Psychiatry 2004;61 (7) 669- 680PubMedGoogle Scholar
17.
First  MSpitzer  RGibbon  MWilliams  J Structured Clinical Interview for Axis I DSM-IV Disorders—Patient Edition.  Washington, DC: American Psychiatric Press Inc; 1994
18.
First  MBGibbon  MSpitzer  RLWilliams  JBBenjamin  LS Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II).  Washington, DC: American Psychiatric Press Inc; 1997
19.
Hamilton  M A rating scale for depression.  J Neurol Neurosurg Psychiatry 1960;2356- 62PubMedGoogle Scholar
20.
Jarrett  RBKraft  DDoyle  JFoster  BMEaves  GGSilver  PC Preventing recurrent depression using cognitive therapy with and without a continuation phase: a randomized clinical trial.  Arch Gen Psychiatry 2001;58 (4) 381- 388PubMedGoogle Scholar
21.
Frank  EPrien  RFJarrett  RBKeller  MBKupfer  DJLavori  PWRush  AJWeissman  MM Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence.  Arch Gen Psychiatry 1991;48 (9) 851- 855PubMedGoogle Scholar
22.
Haddad  P The SSRI discontinuation syndrome.  J Psychopharmacol 1998;12 (3) 305- 313PubMedGoogle Scholar
23.
Rosenbaum  JFZajecka  J Clinical management of antidepressant discontinuation.  J Clin Psychiatry 1997;58 ((suppl 7)) 37- 40PubMedGoogle Scholar
24.
Segal  ZVWilliams  JMTeasdale  JD Mindfulness-Based Cognitive Therapy for Depression: A New Approach to Preventing Relapse.  New York, NY: Guilford Press; 2002
25.
Segal  ZVKennedy  SGemar  MHood  KPedersen  RBuis  T Cognitive reactivity to sad mood provocation and the prediction of depressive relapse.  Arch Gen Psychiatry 2006;63 (7) 749- 755PubMedGoogle Scholar
26.
Michalak  JHeidenreich  TMeibert  PSchulte  D Mindfulness predicts relapse/recurrence in major depressive disorder after mindfulness-based cognitive therapy.  J Nerv Ment Dis 2008;196 (8) 630- 633PubMedGoogle Scholar
27.
Farb  NSegal  ZMayberg  HBean  J McKeon  DAnderson  A Mindfulness training reveals dissociable neural modes of self-reference.  Soc Cogn Affect Neurosci 2007;2 (4) 313- 322doi:10.1093/scan/nsm030PubMedGoogle Scholar
28.
Rush  AJTrivedi  MHIbrahim  HMCarmody  TJArnow  BKlein  DNMarkowitz  JCNinan  PTKornstein  SManber  RThase  MEKocsis  JHKeller  MB The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression.  Biol Psychiatry 2003;54 (5) 573- 583PubMedGoogle Scholar
29.
Keller  MBLavori  PWFriedman  BNielsen  EEndicott  J McDonald-Scott  PAndreasen  NC The Longitudinal Interval Follow-up Evaluation: a comprehensive method for assessing outcome in prospective longitudinal studies.  Arch Gen Psychiatry 1987;44 (6) 540- 548PubMedGoogle Scholar
30.
Fleiss  JLCohen  J Statistical Methods for Rates and Proportions.  New York, NY: John Wiley & Sons Inc; 1973
31.
Cox  DROakes  D Analysis of Survival Data.  London, England: Chapman & Hall; 1984
32.
Segal  ZVTeasdale  JDWilliams  JMGemar  MC The Mindfulness-Based Cognitive Therapy Adherence Scale: inter-rater reliability, adherence to protocol and treatment distinctiveness.  Clin Psychol Psychother 2002;9 (2) 131- 138doi:10.1002/cpp.320Google Scholar
33.
Fawcett  JEpstein  PFiester  SJElkin  IAutry  JHNIMH Treatment of Depression Collaborative Research Program, Clinical management—imipramine/placebo administration manual.  Psychopharmacol Bull 1987;23 (2) 309- 324PubMedGoogle Scholar
34.
Paykel  ESScott  JTeasdale  JDJohnson  ALGarland  AMoore  RJenaway  ACornwall  PLHayhurst  HAbbott  RPope  M Prevention of relapse in residual depression by cognitive therapy: a controlled trial.  Arch Gen Psychiatry 1999;56 (9) 829- 835PubMedGoogle Scholar
35.
Solomon  DALeon  ACMueller  TICoryell  WTeres  JJPosternak  MAJudd  LLEndicott  JKeller  MB Tachyphylaxis in unipolar major depressive disorder.  J Clin Psychiatry 2005;66 (3) 283- 290PubMedGoogle Scholar
36.
Bech  PLönn  SLOverø  KF Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder.  J Clin Psychiatry 2010;71 (2) 121- 129PubMedGoogle Scholar
37.
Nierenberg  AAHusain  MMTrivedi  MHFava  MWarden  DWisniewski  SRMiyahara  SRush  AJ Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report.  Psychol Med 2010;40 (1) 41- 50PubMedGoogle Scholar
38.
Judd  LLPaulus  MJSchettler  PJAkiskal  HSEndicott  JLeon  ACMaser  JDMueller  TSolomon  DAKeller  MB Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness?  Am J Psychiatry 2000;157 (9) 1501- 1504PubMedGoogle Scholar
39.
Dew  MAReynolds  CF  IIIMulsant  BFrank  EHouck  PRMazumdar  SBegley  AKupfer  DJ Initial recovery patterns may predict which maintenance therapies for depression will keep older adults well.  J Affect Disord 2001;65 (2) 155- 166PubMedGoogle Scholar
40.
Keller  MBTrivedi  MHThase  MEShelton  RCKornstein  SGNemeroff  CBFriedman  ESGelenberg  AJKocsis  JHDunner  DLHirschfeld  RMRothschild  AJFerguson  JMSchatzberg  AFZajecka  JMPedersen  RDYan  BAhmed  SMusgnung  JNinan  PT The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: outcomes from the 2-year and combined maintenance phases.  J Clin Psychiatry 2007;68 (8) 1246- 1256PubMedGoogle Scholar
41.
Montgomery  SAEntsuah  RHackett  DKunz  NRRudolph  RLVenlafaxine 335 Study Group, Venlafaxine versus placebo in the preventive treatment of recurrent major depression.  J Clin Psychiatry 2004;65 (3) 328- 336PubMedGoogle Scholar
42.
Strunk  DRStewart  MOHollon  SDDeRubeis  RJFawcett  JAmsterdam  JDShelton  RC Can pharmacotherapists be too supportive? a process study of active medication and placebo in the treatment of depression.  Psychol Med 2010;40 (8) 1379- 1387PubMedGoogle Scholar
43.
Kuyken  WWatkins  EHolden  EWhite  KTaylor  RSByford  SEvans  ARadford  STeasdale  JDDalgleish  T How does mindfulness-based cognitive therapy work?  Behav Res TherPubMed2010;48(11):1105-1112Google Scholar
44.
Goldapple  KSegal  ZGarson  CLau  MBieling  PKennedy  SMayberg  H Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy.  Arch Gen Psychiatry 2004;61 (1) 34- 41PubMedGoogle Scholar
45.
Farb  NAAnderson  AKMayberg  HBean  J McKeon  DSegal  ZV Minding one's emotions: mindfulness training alters the neural expression of sadness.  Emotion 2010;10 (1) 25- 33Google Scholar
46.
Schoenfeld  DA Sample-size formula for the proportional-hazards regression model.  Biometrics 1983;39 (2) 499- 503PubMedGoogle Scholar
47.
Rutherford  BRSneed  JRRoose  SP Does study design influence outcome? the effects of placebo control and treatment duration in antidepressant trials.  Psychother Psychosom 2009;78 (3) 172- 181PubMedGoogle Scholar
48.
Bech  P Fifty years with the Hamilton scales for anxiety and depression: a tribute to Max Hamilton.  Psychother Psychosom 2009;78 (4) 202- 211PubMedGoogle Scholar
Original Article
December 6, 2010

Antidepressant Monotherapy vs Sequential Pharmacotherapy and Mindfulness-Based Cognitive Therapy, or Placebo, for Relapse Prophylaxis in Recurrent Depression

Author Affiliations

Author Affiliations: Centre for Addiction and Mental Health, Toronto, Ontario (Drs Segal, Cooke, and Levitan and Mr Bloch); and Departments of Psychiatry, St Joseph's Healthcare, Hamilton, Ontario (Drs Bieling and Martin), University of Toronto, Toronto (Dr Young), and University of Calgary (Dr MacQueen), Canada.

Arch Gen Psychiatry. 2010;67(12):1256-1264. doi:10.1001/archgenpsychiatry.2010.168
Abstract

Context  Mindfulness-based cognitive therapy (MBCT) is a group-based psychosocial intervention designed to enhance self-management of prodromal symptoms associated with depressive relapse.

Objective  To compare rates of relapse in depressed patients in remission receiving MBCT against maintenance antidepressant pharmacotherapy, the current standard of care.

Design  Patients who met remission criteria after 8 months of algorithm-informed antidepressant treatment were randomized to receive maintenance antidepressant medication, MBCT, or placebo and were followed up for 18 months.

Setting  Outpatient clinics at the Centre for Addiction and Mental Health, Toronto, Ontario, Canada, and St Joseph's Healthcare, Hamilton, Ontario.

Participants  One hundred sixty patients aged 18 to 65 years meeting DSM-IV criteria for major depressive disorder with a minimum of 2 past episodes. Of these, 84 achieved remission (52.5%) and were assigned to 1 of the 3 study conditions.

Interventions  Patients in remission discontinued their antidepressants and attended 8 weekly group sessions of MBCT, continued taking their therapeutic dose of antidepressant medication, or discontinued active medication and were switched to placebo.

Main Outcome Measure  Relapse was defined as a return, for at least 2 weeks, of symptoms sufficient to meet the criteria for major depression on module A of the Structured Clinical Interview for DSM-IV.

Results  Intention-to-treat analyses showed a significant interaction between the quality of acute-phase remission and subsequent prevention of relapse in randomized patients (P = .03). Among unstable remitters (1 or more Hamilton Rating Scale for Depression score >7 during remission), patients in both MBCT and maintenance treatment showed a 73% decrease in hazard compared with placebo (P = .03), whereas for stable remitters (all Hamilton Rating Scale for Depression scores ≤7 during remission) there were no group differences in survival.

Conclusions  For depressed patients achieving stable or unstable clinical remission, MBCT offers protection against relapse/recurrence on a par with that of maintenance antidepressant pharmacotherapy. Our data also highlight the importance of maintaining at least 1 long-term active treatment in unstable remitters.

×